Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
09/04/2020 | 05:59pm EDT

Item 8.01 Other Events.

As previously reported on a Form 8-K filed on September 2, 2020, on August 28, 2020, Celsion Corporation, a Delaware corporation ("Celsion"), entered into the First Amendment (the "Amendment") to the Venture Loan and Security Agreement with Horizon Technology Finance Corporation ("Horizon") dated June 27, 2018 (the "Initial Horizon Credit Agreement"). Pursuant to the Amendment, one-half of the aggregate warrants previously issued in connection with the Initial Horizon Credit Agreement were canceled, and Celsion issued Horizon new warrants exercisable at a per share exercise price equal to $1.01 for a total of 247,525 shares of Celsion's common stock (the "New Warrants").

For a complete description of the terms and conditions of the Amendment and the New Warrants, please refer to such agreements which are incorporated herein by reference and attached to this report as Exhibits 10.1 and 4.1, respectively.

Item 9.01 Financial Statements and Exhibits.



(d)



Exhibit No.   Exhibit Name
4.1             Form of Amended and Restated Warrant
10.1            First Amendment of Venture Loan and Security Agreement, dated as
              of August 1, 2020, by and among Celsion Corporation, Horizon Funding
              I, LLC, Horizon Funding Trust 2019-1, and Horizon Technology Finance
              Corporation, as Collateral Agent.

© Edgar Online, source Glimpses


share with twitter share with LinkedIn share with facebook
All news about CELSION CORPORATION
10/30CELSION ALERT : Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsui..
BU
10/16CELSION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
AQ
10/12CELSION CORPORATION : Issues Letter to Stockholders
AQ
10/12Celsion Corporation Issues Letter to Stockholders
GL
09/08CELSION CORP : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
09/08CELSION : Announces Common Stock Purchase Agreement with Lincoln Park Capital an..
AQ
09/08Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital a..
GL
09/04CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/02CELSION CORP : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
09/02Celsion Corporation Restructures its Strategic Loan Facility
GL
More news
Financials (USD)
Sales 2020 0,51 M - -
Net income 2020 -19,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,71x
Yield 2020 -
Capitalization 17,1 M 17,1 M -
Capi. / Sales 2020 33,9x
Capi. / Sales 2021 68,4x
Nbr of Employees 29
Free-Float 98,6%
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 4,00 $
Last Close Price 0,47 $
Spread / Highest target 746%
Spread / Average Target 746%
Spread / Lowest Target 746%
EPS Revisions
Managers
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION-72.34%18
GILEAD SCIENCES, INC.-10.51%73 380
REGENERON PHARMACEUTICALS44.76%58 486
VERTEX PHARMACEUTICALS-4.84%53 919
WUXI APPTEC CO., LTD.71.31%40 739
BEIGENE, LTD.78.89%27 143